Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RCHOP + R-miniCHOP
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
RCHOP + R-miniCHOP refers to the use of two related combination chemotherapy regimens for the treatment of non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma (DLBCL). Both regimens combine five drugs: - Rituximab (a monoclonal antibody targeting CD20 on B cells) - Cyclophosphamide (an alkylating agent/chemotherapy) - Doxorubicin (an anthracycline chemotherapy) - Vincristine (a vinca alkaloid chemotherapy) - Prednisolone or prednisone (a corticosteroid) RCHOP is the standard-dose regimen used in most adults. R-miniCHOP is a reduced-intensity version designed for elderly or frail patients, especially those over 80 years old, to reduce toxicity while maintaining efficacy[1][4]. Both regimens work by combining immunotherapy with cytotoxic agents and steroids to destroy malignant lymphocytes.
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on RCHOP + R-miniCHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RCHOP + R-miniCHOP.